Developing therapeutic agents that upregulate SIRT3 and protect the mitochondria could have broad implications for kidney protection prior to AKI-inducing stimuli (i.e., surgery, transplantation) and during recovery following AKI. The gene discussed is SIRT3; the disease is acute kidney injury.